02:27 , May 18, 2018 |  BC Week In Review  |  Financial News

Acousia raises $12M in series B

Hearing loss company Acousia Therapeutics GmbH (Tübingen, Germany) raised €10 million ($12 million) on May 14 in a series B round led by LBBW Venture Capital. Fellow new investors Creathor Ventures and Bregua Corp. and...
12:05 , May 14, 2018 |  BC Extra  |  Financial News

Acousia raises €10M in series B

Hearing loss company Acousia Therapeutics GmbH (Tübingen, Germany) raised €10 million ($12 million) in a series B round led by LBBW Venture Capital. Fellow new investors Creathor Ventures and Bregua Corp. and existing investors Boehringer...
19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
22:03 , Jan 6, 2017 |  BC Week In Review  |  Company News

Axxam, Acousia deal

Axxam transferred undisclosed assets to Acousia's R&D programs. Acousia is developing small molecules to treat sensorineural hearing loss and to prevent hearing loss in at-risk patients. Last month, Axxam participated in Acousia’s €2.5 million ($2.6...
17:18 , Dec 16, 2016 |  BC Week In Review  |  Financial News

Acousia completes venture financing

Acousia raised €2.5 million ($2.6 million) in a venture round led by Boehringer Ingelheim Venture Fund. KfW and Axxam S.p.A. also participated. Acousia Therapeutics GmbH, Tübingen, Germany  ...
08:00 , Jan 4, 2016 |  BioCentury  |  Emerging Company Profile

Regrowing hearing

Acousia Therapeutics GmbH is developing small molecules to treat sensorineural hearing loss that could lead to better speech perception than a clinical-stage gene therapy that also aims to regenerate hair cells. With an investment from...